| Autor: |
Evans TR; Department of Medical Oncology, Charing Cross Hospital, London, England., Rowlands MG, Jarman M, Coombes RC |
| Jazyk: |
angličtina |
| Zdroj: |
The Journal of steroid biochemistry and molecular biology [J Steroid Biochem Mol Biol] 1991 Oct; Vol. 39 (4A), pp. 493-9. |
| DOI: |
10.1016/0960-0760(91)90243-x |
| Abstrakt: |
Estrone sulfatase is an important mechanism of local synthesis of biologically active estrogens in human breast cancer. The human placental microsome and breast carcinoma mitochondrial/microsomal estrone sulfatase activity were characterized and inhibition studies performed. The Km of the placental tissue enzyme was 6.83 microM, Vmax 0.015 nmol/min/mg, and for the breast carcinoma tissue Km was 8.91 microM and Vmax 0.022 nmol/min/mg. Danazol produced a significant inhibition of estrone sulfatase (20% with 50 microM danazol). No significant inhibition was seen in the presence of aminoglutethimide, rogletimide, tamoxifen, 4-hydroxyandrostenedione, stilboestrol, or any metabolites of danazol or tamoxifen. Studies with synthetic and naturally occurring steroids demonstrated that the presence of a sulfate group at the 3 position to be the most important factor in determining inhibition, and the most potent inhibitor was 5 alpha-androstene-3 beta,17 beta-diol-3-sulfate (Ki of 2.0 microM). The naturally occurring 3-sulfated steroids all demonstrated competitive inhibition. These studies could form the basis for the design of a potent estrone sulfatase inhibitor which would have potential therapeutic activity in the management of breast cancer. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
